Answers are grounded in this paper and cite their sources.
Since the discovery and description of natural killer (NK) cells, approximately 45 years ago by Rolf Kiessling and Ronald B Herberman, and the subsequent immunotherapy renascence era, the interest in NK cell-based immunotherapy has dramatically increased over the last 5 years. Immune ‘checkpoint’ inhibitors represent the most significant advance in cancer treatment in the last 30 years. However, their effectiveness is limited to tumors with infiltrating tumor-specific cytotoxic T lymphocytes, where resistance to checkpoint inhibition has been commonly observed. Natural killer (NK) cells are the innate equivalent to cytotoxic T lymphocytes and are able to spontaneously detect and kill transformed cells, thus contributing to cancer immune surveillance. Mature, functional NK cells are frequent in blood and lymphoid organs, yet cancerous cells are still able to efficiently evade NK cell detection, resulting in metastases in vital organs that ultimately lead to death. Key advances are thus required in order to target NK cells effectively to tumors. Despite these unknowns, NK cell-based therapies are highly desirable as they are predicted to elicit fewer side effects than their T-cell counterparts (e.g. graft-versus-host disease [GvHD] following allogeneic transplantation and cytokine response syndrome [CRS]). NK cell-based therapies also do not require prior sensitisation or clonal expansion. Consequently, NK cells have been the focus of intense research leading to remarkable translational progress over the past 5 years. This Special Feature of Clinical & Translational Immunology (CTI) is a collaboration amongst leading scientists from the fields of NK cell biology, tumor immunity, clinical translation, inflammation and vaccinology to expound the recent discoveries of novel regulatory mechanisms for NK cell activity and how targeting these pathways could revolutionise the treatment of a variety of diseases. Collectively, this series of articles provides an updated overview of the emerging roles for NK cells and this fascinating cellular target for immunotherapy (Figure 1). Opening this CTI Special Feature, Xing and Ferrari de Andrade provide an synopsis of a recent and unexpected mechanism by which cancer or infected cells are able to hijack NK cell-mediated immunosurveillance. NK cells take advantage of multiple activating receptors to sense unusual cellular alterations, where this recognition is canonically regulated by the NK group 2D (NKG2D)-activating receptor. NKG2D detects the expression of stress ligands such as the MHC class I polypeptide-related sequence A (MICA) or MICB, which are upregulated on the cell surface in response to the cellular stress associated with tumorigenesis or viral infections. Previous work by the group demonstrated that MICA/MICB shedding by cancer cells provides a strategy for immunoevasion from NK cell surveillance and that therapeutics preventing this shedding mechanism are a novel immunotherapy approach to restore NKG2D-mediated surveillance. Thus, determining further strategies to prevent the shedding of these ligands is an exciting new research niche in immunotherapy with untapped potential for maximising NK cell responses against altered cells.
No takes yet. Share an insight, caveat, or question.
Fernando Souza-Fonseca-Guimarães (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: